TXMD (TherapeuticsMD) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Change In Receivables?

TherapeuticsMD's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means TherapeuticsMD's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

TherapeuticsMD's change in receivables for the fiscal year that ended in Dec. 2024 was $0.00 Mil. It means TherapeuticsMD's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

TherapeuticsMD's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. TherapeuticsMD's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. TherapeuticsMD's liquidation value for the three months ended in Dec. 2024 was $-6.39 Mil.

TherapeuticsMD Change In Receivables Historical Data

The historical data trend for TherapeuticsMD's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Change In Receivables Chart

TherapeuticsMD Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-8.22

-4.33

TherapeuticsMD Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

TherapeuticsMD Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

TherapeuticsMD (NAS:TXMD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

TherapeuticsMD's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.667	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, TherapeuticsMD's accounts receivable are only considered to be worth 75% of book value:

TherapeuticsMD's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.059	-	11.452	+	0.75 * 0	+	0.5 * 0
=	-6.39

TherapeuticsMD Change In Receivables Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

TherapeuticsMD Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

29TA:Germany

Address

951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431

Website

https://www.therapeuticsmd.com

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Executives

Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Marlan D Walker	officer: General Counsel	951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Collins Cooper C.	director	33219 FOREST WEST DRIVE, MAGNOLIA TX 77354
Joseph Ziegler	officer: Principal Financial Officer	1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan	officer: CAO and VP of Finance	6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman	officer: Chief Business Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts	director	C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Jules A. Musing	director	9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Paul Bisaro	director
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017